GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcturus Therapeutics Holdings Inc (NAS:ARCT) » Definitions » Cyclically Adjusted Book per Share

Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Cyclically Adjusted Book per Share : $10.51 (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Arcturus Therapeutics Holdings Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Arcturus Therapeutics Holdings's adjusted book value per share for the three months ended in Mar. 2024 was $9.807. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $10.51 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Arcturus Therapeutics Holdings's average Cyclically Adjusted Book Growth Rate was -8.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-06-09), Arcturus Therapeutics Holdings's current stock price is $31.82. Arcturus Therapeutics Holdings's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $10.51. Arcturus Therapeutics Holdings's Cyclically Adjusted PB Ratio of today is 3.03.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Arcturus Therapeutics Holdings was 3.72. The lowest was 1.24. And the median was 2.21.


Arcturus Therapeutics Holdings Cyclically Adjusted Book per Share Historical Data

The historical data trend for Arcturus Therapeutics Holdings's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcturus Therapeutics Holdings Cyclically Adjusted Book per Share Chart

Arcturus Therapeutics Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 10.38 11.24 10.81

Arcturus Therapeutics Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.45 11.40 11.44 10.81 10.51

Competitive Comparison of Arcturus Therapeutics Holdings's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Arcturus Therapeutics Holdings's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arcturus Therapeutics Holdings's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcturus Therapeutics Holdings's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Arcturus Therapeutics Holdings's Cyclically Adjusted PB Ratio falls into.



Arcturus Therapeutics Holdings Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Arcturus Therapeutics Holdings's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=9.807/131.7762*131.7762
=9.807

Current CPI (Mar. 2024) = 131.7762.

Arcturus Therapeutics Holdings Quarterly Data

Book Value per Share CPI Adj_Book
201406 18.103 100.560 23.723
201409 13.268 100.428 17.410
201412 10.188 99.070 13.551
201503 0.000 99.621 0.000
201506 12.809 100.684 16.765
201509 11.594 100.392 15.219
201512 17.609 99.792 23.253
201603 16.506 100.470 21.649
201606 15.184 101.688 19.677
201609 13.363 101.861 17.288
201612 0.401 101.863 0.519
201703 11.233 102.862 14.391
201706 10.335 103.349 13.178
201709 9.724 104.136 12.305
201712 3.171 104.011 4.017
201803 0.000 105.290 0.000
201806 1.657 106.317 2.054
201809 1.320 106.507 1.633
201812 1.273 105.998 1.583
201903 0.593 107.251 0.729
201906 1.648 108.070 2.010
201909 2.373 108.329 2.887
201912 1.704 108.420 2.071
202003 1.120 108.902 1.355
202006 4.533 108.767 5.492
202009 10.691 109.815 12.829
202012 15.140 109.897 18.154
202103 13.397 111.754 15.797
202106 11.610 114.631 13.346
202109 9.834 115.734 11.197
202112 8.654 117.630 9.695
202203 6.996 121.301 7.600
202206 6.458 125.017 6.807
202209 5.499 125.227 5.787
202212 10.179 125.222 10.712
202303 12.399 127.348 12.830
202306 10.731 128.729 10.985
202309 10.480 129.860 10.635
202312 10.381 129.419 10.570
202403 9.807 131.776 9.807

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Arcturus Therapeutics Holdings  (NAS:ARCT) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Arcturus Therapeutics Holdings's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=31.82/10.51
=3.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Arcturus Therapeutics Holdings was 3.72. The lowest was 1.24. And the median was 2.21.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Arcturus Therapeutics Holdings Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Arcturus Therapeutics Holdings's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
10628 Science Center Drive, Suite 250, San Diego, CA, USA, 92121
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.
Executives
Pad Chivukula officer: Chief Scientific Officer & COO 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Keith C Kummerfeld officer: See Remarks 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
John Markels director C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804
Joseph E Payne director, 10 percent owner, officer: President and CEO 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Jing L. Marantz director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Ultragenyx Pharmaceutical Inc. director, 10 percent owner 60 LEVERONI COURT, NOVATO CA 94949
Lance Kurata officer: Chief Legal Officer 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Andy Sassine officer: Chief Financial Officer 82 DEVONSHIRE STREET, BOSTON MA 02109
Steven George Hughes officer: Chief Development Officer 6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
James F Barlow director 2525 DUPONT DR, IRVINE CA 92612
Edward W Holmes director C/O TULARIK INC, TWO CORP DRIVE SOUTH, SAN FRANCISCO CA 8608257208
Peter C Farrell director RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Karah Herdman Parschauer director 60 LEVERONI COURT, NOVATO CA 94949

Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Headlines

From GuruFocus